Vinay Prasad, MD, MPH, policy research and oncologist, dissects with me the theory of “value-based care.” How can this concept be used as a tool to better patient care and lower the cost of cancer therapies? Are current value estimations useful in this space?
How do we define value? I think it’s in the eyes of the beholder. Let’s hear what Dr. Prasad has to say. Vinay is very vocal and will not shy away in this episode from describing his views.
Dr Prasad’s podcast “Plenary Session” can be found here. This podcast is produced by the Journal of Clinical Pathways.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
